

## 2021 Extraordinary General Meeting

### Board of Director Candidate

#### **Rafaèle Tordjman (Proposed Board Member)**

Dr Rafaèle Tordjman, MD PhD, has been an investor in life sciences for almost 20 years. She joined Sofinnova Partners, a Paris-based venture capital firm, in 2001, as an analyst. She became co-leader and Managing partner with €1.5 billion in assets under management, which she held until 2017.

During her time at Sofinnova, Dr. Tordjman has invested in and served on the boards of a number of life science companies, including Ascendis [ASND], DBV Technologies [DBV], Lysogene [LYS], MedDay, Enyo Pharma, Nucana Biomed [NCNA], Flexion Therapeutics [FLXN], Obseva [OBSV] and Preglem, before the company was sold to Gedeon Richter.

Prior to joining Sofinnova Partners, Dr. Tordjman worked as a physician and researcher in haemato-oncology. After five years working at the Paris University Hospitals as a medical doctor specialising in internal medicine and clinical hematology, she presented her doctoral thesis on Haematopoiesis and Angiogenesis, which she obtained in 2000. Dr. Tordjman then completed her post-doctoral work in immunology at INSERM, Cochin Hospital, and published in Nature Immunology among others. In 2002, she also completed a management training course at INSEAD.

In 2018, Dr. Tordjman founded Jeito Capital, an independent investment company dedicated to biopharma/biotech to establish a model of continuous financing and to invest in the next generation of leaders in medical innovation. Jeito I raised €534 million (\$630 million) in September 2021, becoming the largest European fund in Life Sciences. She seats at the Board of InnoSkel (Chair), and Alentis Therapeutics (Chair) as representative of Jeito.

To engage more women in the life sciences industry, in 2010 Dr. Tordjman founded the association W.I.T.H. (Women Innovating Together in Healthcare) that now has a global membership of 500 women representing the full chain of medical innovation.

In September 2020, Dr. Tordjman was awarded Chevalier de la Légion d'Honneur, France's highest distinction, for her achievements.

In July 2021, Dr. Tordjman was appointed by Agnès Pannier-Runacher, Minister Delegate for Industry and Franck Riester, Minister Delegate for Foreign Trade and Economic Attractiveness to promote the French biotech ecosystem among leading international players